NIKKEI 225
40,074.69 +443.63 (+1.12%) HANG SENG
17,769.14 +50.53 (+0.29%) CRUDE OIL
83.17 +0.36 (+0.43%) GOLD FUTURES
2,338.60 +5.20 (+0.22%) DOW
39,331.85 +162.33 (+0.41%) Bitcoin GBP
48,807.69 -909.87 (-1.83%)
LEGN Dec 2024 110.000 call
| Previous close | 2.1300 |
| Open | N/A |
| Bid | 0.0000 |
| Ask | 2.4000 |
| Strike | 110.00 |
| Expiry date | 2024-12-20 |
| Day's range | 2.1300 - 2.1300 |
| Contract range | N/A |
| Volume | |
| Open interest | 10 |
GlobeNewswireLegend Biotech Announces Positive Overall Survival Results of Landmark Phase 3 CARTITUDE-4 Trial in Multiple Myeloma
CARVYKTI® demonstrated statistically significant and clinically meaningful improvement in overall survival in second interim analysisSOMERSET, N.J., July 02, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today positive overall survival results from CARTITUDE-4, an ongoing, global randomized, open-label Phase 3 study evaluating the efficacy and safety of CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) versus pomali
Insider MonkeyDoes Legend Biotech (LEGN) Have a Long Runway for Growth?
TimesSquare Capital Management, an equity investment management company, released its “U.S. Focus Growth Strategy” first-quarter investor letter. A copy of the letter can be downloaded here. In the first quarter, the strategy returned 11.72% (gross) and 11.49% (net) compared to 9.50% for the Russell Midcap Growth Index. The first-quarter performance was barbelled, particularly for U.S. […]
Business WireLegend Biotech Shares Data on the Earliest Use to Date of CARVYKTI® in the Treatment of Multiple Myeloma and Important Subgroup Analyses at ASCO and EHA
SOMERSET, N.J., June 03, 2024--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today results for the first time from the Phase 2 CARTITUDE-2 Cohort D study in multiple myeloma patients. Results showed patients with less than a complete response (CR) after front-line autologous stem cell transplant (ASCT) experienced deep and durable responses following a single infusion of CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) with or without lena
